FFR Benefit Prompts St. Jude to Halt FAME II Study

The sponsor of the FAME II trial, which is assessing the efficacy of fractional flow reserve (FFR) as a tool to improve stenting outcomes, said it is halting enrollment after an analysis revealed a significant benefit for patients in the FFR arm.
MedPage Today